Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort

Although hypomethylating agents (HMAs) are frequently used in the frontline treatment of older acute myeloid leukemia (AML) patients, little is known about their effectiveness in relapsed or primary treatment–refractory (RR)-AML. Using an international multicenter retrospective database, we studied...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Blood Adv
Main Authors: Stahl, Maximilian, DeVeaux, Michelle, Montesinos, Pau, Itzykson, Raphael, Ritchie, Ellen K., Sekeres, Mikkael A., Barnard, John D., Podoltsev, Nikolai A., Brunner, Andrew M., Komrokji, Rami S., Bhatt, Vijaya R., Al-Kali, Aref, Cluzeau, Thomas, Santini, Valeria, Fathi, Amir T., Roboz, Gail J., Fenaux, Pierre, Litzow, Mark R., Perreault, Sarah, Kim, Tae Kon, Prebet, Thomas, Vey, Norbert, Verma, Vivek, Germing, Ulrich, Bergua, Juan Miguel, Serrano, Josefina, Gore, Steven D., Zeidan, Amer M.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2018
Teme:
Myeloid Neoplasia
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5916007/
https://ncbi.nlm.nih.gov/pubmed/29685952
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018016121
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki